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Poster Session I S231approach have been identified. Recently CD40-activated B cells
(CD40-B) have been studied as complementary antigen presenting
cells. They can be expanded from small amounts of PB at.95% pu-
rity underGMP-like conditions and efficiently prime and expand na-
ı¨ve T cells in vitro. Importantly these cells are available at virtually
unlimited amounts for high-dose, high-frequency vaccination con-
sidered crucial for the control of cancer in vivo.
Methods and Results: For preclinical in vivo testing using high-
dose, repetitive vaccinations with CD40-B we developed a murine
system to study their ability to induce immune responses in vivo.
mCD40B are generated from murine splenocytes by co-culture
with murine CD40-Ligand and addition of IL-4. mCD40B cells
could be expanded more than 6-fold within 14 days and .90% pu-
rity. mCD40B were used to establish a vaccination model to study
induction of tumor- and auto-antigen specific immune responses
as well as toxicity of very-high-dose injections (VHD) in B6 mice.
To determine long-term toxicity mice were vaccinated twice weekly
for 5 weeks using high-doses (310^6  110^8/kg) of mCD40B.
This is about 2-3 log higher than currently used in DC vaccinations
in humans. Acute toxicity was assessed by vaccinatingmice once with
VHD (110^7 3.310^8/kg). There was no difference in survival,
weight and clinical appearance compared to control mice. Histo-
pathological assessment did not reveal any pathologic changes. Mu-
rine Mixed Lymphocyte Reaction was established to investigate the
immune-stimulatory capacity of mCD40B in comparison to mDC
through detection of T cell proliferation in vitro. Immune monitor-
ing by intracellular cytokine staining for IFN-g and assessment of in
vivo cytotoxicity revealed that mCD40B vaccination leads to in-
creased IFN-g production by activated T cells and specific lysis of
CFSE-labelled peptide-pulsed target cells.
Conclusion:Based on these findings thatmCD40B induceT cell re-
sponses in vitro and in vivo we are now developing the optimal
mCD40B vaccination algorithm for preventive and therapeutic
treatment of B16-Melanoma in B6 mice as a next step towards future
clinical application in post transplant donor-lymphocyte-infusion or
vaccination.ransplant outcomes
End-point
All patients
(n5 30) MRD (n5 10) CB (n5 20) p value
-year OS
(95%CI)
47% (28%-66%) 50% (19%-80%) 44% (20%-68%) 0.9
-year PFS
(95%CI)
39% (21%57%) 40% (10%-70%) 39% (27%-60%) 0.8
-month TRM
(95%CI)
13% (1%-26%) 20% (0-43%) 10% (0-23%) 0.6197
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT)
USING FLUDARABINE/TREOSULFAN CONDITIONING REGIMEN COM-
PARED WITH BUSULFAN-BASED MYELOABLATIVE AND REDUCED-IN-
TENSITY CONDITIONING IN PATIENTS WITH AML AND MDS; RELATIVE
OUTCOMES DEPEND ON DISEASE STATUS AT SCT
Shimoni, A., Shem-Tov, N., Rand, A., Volchek, Y., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Allogeneic SCT with both myeloablative (MAC) and reduced-in-
tensity conditioning (RIC) is effective therapy in AML/MDS. How-
ever, the relative merits of each differ in different settings.
Fludarabine/treosulfan (FT) has been reported as an effective regi-
men in AML/MDS with limited toxicity. However, the relative
dose intensity and expected outcomes with FT in the different
SCT settings, compared with Busulfan (Bu)-based regimens, is not
well defined. We analyzed the outcomes of 298 pts with AML/
MDS given SCT from sibling (n5 153) or unrelated (n5 145) do-
nors. Pts meeting standard eligibility criteria forMACwere given iv-
BuCy (n5 81). Pts at high risk for MAC were given fludarabine and
reduced doses of ivBu (6.4 mg/kg, FB2, n5 91), high dose Bu (FB4,
12.8 mg/kg, n5 63) or treosulfan (30-36 gr/m2, n5 63). Non-re-
lapse mortality was 17%,18%,18% and 20% with FB2,FB4,FT
and BuCy, respectively (p5NS). With a median follow-up of 38
months (1-115), estimated 5-yr overall survival (OS) was
36%,33%,43% and 41%, respectively (p5NS). Multivariate analy-
sis (MVA) defined age. 50 [HR 1.5 (1-2.2), p5 0.05)], active dis-
ease at SCT [HR 2.3 (1.6-3.2), p\0.001)] and unrelated donor
[HR 1.5 (1-2.0), p5 0.02)] as risk factors for shorter OS. The condi-
tioning regimen was not predictive.When the analysis was limited to
pts in remission (n5 126), OSwas 51%,43%,58%, and 43%, respec-
tively. MVA identified age. 50 as an adverse factor, while SCT us-
ing FB2 or FT was associated with longer OS [HR 0.3 (0.2-0.7),
p5 0.002)]. When the analysis was limited to pts with active disease
(n5 172), either chemo-refractory (n5 93) or untreated (n5 79),OS was 12%,25%,32%, and 36%, respectively. MVA identified
chemo-refractory disease as the major adverse factor for OS [HR
2.2 (1.5-3.3), p5 0.001)], while SCT using BuCy or FT was associ-
ated with longer OS [HR 0.7 (0.5-1.0), p5 0.06)]. In conclusion,
dose intensity is associated with different outcomes in the different
settings. In pts in remission, outcome is mostly related to SCT tox-
icity resulting in an advantage to less intensive regimens, such as
FB2, while FT shares this characteristic. In pts with active disease,
outcome is dominated by the risk for relapse, leading to advantage
of more intensive regimens, such as BuCy. FT shares this character-
istic mainly in pts with no true chemo-refractoriness and has an ad-
vantage over FB2 in this setting. FT should be considered a reduced
toxicity myeloablative conditioning that is feasible in pts ineligible
for MAC.198
SIMILAR AND PROMISING OUTCOMES IN OLDER AML PATIENTS IN FIRST
COMPLETE REMISSION AFTER REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD AND SIBLING DONOR TRANSPLANTATION
Oran, B., Quing, C., Brunstein, C., Majhail, N., Weisdorf, D. University
of Minnesota, Minneapolis, MN
Background: AML has a worse prognosis in older patients indepen-
dent of karyotype abnormalites at the time of diagnosis. However
this group has not been adequately represented in major trials eval-
uating the role of allogeneic allogeneic hematopoietic stem cell
transplantation (HSCT) in AML. Here we present our results with
allogeneic HSCT in older AML patients in first complete remission
(CR1).
Methods:We retrospectively analyzed 30 consecutive patients$ 55
years who underwent their first HSCTwith a matched related donor
(MRD) or cord blood (CB) at the University of Minnesota for AML
in CR1 between January 1995 and December 2007. Study outcomes
were overall survival (OS), progression free survival (PFS) and trans-
plant related mortality (TRM).
Results: Median age was 60 (range 55-68) years; 8 had evolved
from MDS. Thirteen (43%) patients had intermediate risk (all
with normal karyotype) and 17 (57%) had poor risk karyotype.
Donors were MRD (n5 10) and CB (n5 20). Median time
from diagnosis to HSCT was 4.5 months (range 2.6-14.4). Re-
duced intensity conditioning was used in all cases and 27 of 30
(90%) received total-body irradiation (200 cGy), cyclophospha-
mide and fludarabine. Graft versus host disease (GVHD) prophy-
laxis was cyclosporine and mycophenolate mofetil in 27 of 30
patients (90%).
The median follow-up of survivors was 35.3 months (range 9.4-
62.4 months). The probability of 3-year OS was 50% (95% confi-
dence interval (CI), 19%-80%) for MRD and 44% (95% CI, 20%-
68%) for CB (p5 0.9) (Table 1). The probability of 3-year PFS
was 40% (95%CI, 10%-70%) for MRD and 39% (95% CI, 27%-
60%) for CB (p5 0.8). On univariate analysis, poor risk karyotype
and time to transplantation from diagnosis had no impact on disease
outcomes. Grade II-IV aGVHDwas observed in 9 patients (4 MRD
and 5 CB). Chronic GVHD was documented in 10 patients (33%).
Thirteen patients are alive at last contact. Eight of 13 were in remis-
sion and free of all immunosuppression at a median of 24 months
(range 6-32 months). The primary causes of death were relapse
(MRD5 1, CB5 7), infection (MRD5 1, CB5 3), acute GVHD
(MRD5 2) and others. The 6-month TRM was 20% (95%CI,T
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